Global Live Vaccines Market Overview
Western Market Research estimates that the Live Vaccines Market was valued at USD xxxx million in 2025 and is projected to reach USD xxxx million by 2036, expanding at a CAGR of xx% during the forecast period 2026–2036.
Live vaccines—formulated using weakened (attenuated) pathogens—stimulate strong and durable immune responses, often with fewer doses than inactivated vaccines. They are widely used in national immunization programs for diseases such as measles, mumps, rubella, varicella, rotavirus, and yellow fever. Market growth is underpinned by expanding immunization coverage, technological advancements in attenuation and stabilization, and increasing public-health investments worldwide.
The Global Live Vaccines Market Report 2026 delivers an in-depth assessment of market size, product mix, manufacturing dynamics, regulatory environments, competitive positioning, and long-term growth prospects, based on extensive primary and secondary research spanning policy frameworks, epidemiology, cold-chain logistics, and innovation pipelines.
Impact of COVID-19 on the Live Vaccines Market
The COVID-19 pandemic had a mixed impact on the live vaccines market in 2020. Short-term disruptions included delayed routine immunizations, supply-chain interruptions, and constrained cold-chain capacity. However, recovery was driven by:
-
Resumption and catch-up of national immunization programs
-
Heightened awareness of preventive healthcare
-
Strengthened vaccine manufacturing and distribution infrastructure
Post-pandemic, governments and global health agencies renewed commitments to routine vaccination, supporting steady market recovery.
Global Live Vaccines Market Segmentation
By Vaccine Type
-
Monovalent Live Vaccines
-
Multivalent Live Vaccines
By Disease Indication
-
Measles, Mumps & Rubella (MMR)
-
Varicella
-
Rotavirus
-
Yellow Fever
-
Oral Polio Vaccine (OPV)
-
Others
By Age Group / Application
-
Children
-
Adults
By End User
-
Public Immunization Programs
-
Hospitals & Clinics
-
Travel & Specialty Vaccination Centers
Regional Analysis
North America
North America represents a significant share of the market due to robust immunization schedules, strong regulatory oversight, and advanced cold-chain infrastructure. Government procurement and school-entry vaccination requirements sustain stable demand.
Europe
Europe is a mature market with high vaccination coverage and strong pharmacovigilance. Growth remains steady, supported by booster programs, travel vaccinations, and continuous updates to national immunization guidelines.
Asia-Pacific
Asia-Pacific is expected to record the fastest growth over the forecast period. Large birth cohorts, expanding public health funding, local manufacturing capacity, and international immunization initiatives are key drivers in China, India, and Southeast Asia.
South America
The region shows moderate growth, supported by national immunization campaigns and improving access to vaccines, particularly in Brazil and Argentina.
Middle East & Africa
Growth is driven by international health partnerships, expanding immunization coverage, and investments in cold-chain logistics, though access disparities persist in low-income areas.
Key Players in the Global Live Vaccines Market
Major companies operating in the market include:
-
Merck
-
GlaxoSmithKline
-
Pfizer
-
Novartis
-
Astellas Pharma
-
Emergent BioSolutions
-
AstraZeneca
-
Serum Institute of India
-
Sanofi
-
Biological E
Competition is characterized by government tenders, long-term supply agreements, manufacturing scale, and regulatory compliance.
Porter’s Five Forces Analysis
-
Threat of New Entrants: Low
High capital requirements, stringent regulations, and complex manufacturing deter new entrants. -
Bargaining Power of Suppliers: Moderate
Specialized biological inputs and cold-chain components increase supplier importance. -
Bargaining Power of Buyers: High
Governments and international agencies negotiate large-volume contracts at competitive prices. -
Threat of Substitutes: Moderate
Inactivated and subunit vaccines may substitute in certain indications. -
Competitive Rivalry: High
Intense competition among multinational and large regional manufacturers.
SWOT Analysis
Strengths
-
Strong and durable immune response
-
Established inclusion in national immunization programs
-
Long clinical history and proven efficacy
Weaknesses
-
Cold-chain dependency
-
Limited suitability for immunocompromised patients
Opportunities
-
Expansion in emerging economies
-
Development of thermostable live vaccines
-
Combination and multivalent formulations
Threats
-
Vaccine hesitancy
-
Supply-chain disruptions
-
Competition from newer vaccine platforms
Trend Analysis
-
Expansion of multivalent live vaccines
-
Focus on thermostability and cold-chain optimization
-
Increased public-private partnerships for vaccine access
-
Growth of regional manufacturing hubs
-
Integration of digital systems for immunization tracking
Market Drivers and Challenges
Drivers
-
Rising global immunization coverage
-
Government and NGO-led vaccination initiatives
-
High efficacy and long-lasting immunity
Challenges
-
Cold-chain logistics complexity
-
Regulatory and safety monitoring requirements
-
Public perception and vaccine hesitancy
Value Chain Analysis
-
Strain Development & Attenuation
-
Cell Culture & Fermentation
-
Formulation & Stabilization
-
Quality Control & Regulatory Approval
-
Cold-Chain Distribution
-
Public & Private Procurement
-
Administration & Post-Marketing Surveillance
Strategic Recommendations for Stakeholders
-
Manufacturers: Invest in scalable production and thermostable formulations
-
Governments: Strengthen cold-chain infrastructure and procurement planning
-
Healthcare Providers: Enhance vaccination awareness and compliance programs
-
Investors: Focus on Asia-Pacific and Africa-linked manufacturing expansion
-
Global Health Agencies: Support funding and technology transfer initiatives
1. Market Overview of Live Vaccines
1.1 Live Vaccines Market Overview
1.1.1 Live Vaccines Product Scope
1.1.2 Market Status and Outlook
1.2 Live Vaccines Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Live Vaccines Historic Market Size by Regions
1.4 Live Vaccines Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Live Vaccines Sales Market by Type
2.1 Global Live Vaccines Historic Market Size by Type
2.2 Global Live Vaccines Forecasted Market Size by Type
2.3 Monovalent Live Vaccines
2.4 Multivalent Live Vaccines
3. Covid-19 Impact Live Vaccines Sales Market by Application
3.1 Global Live Vaccines Historic Market Size by Application
3.2 Global Live Vaccines Forecasted Market Size by Application
3.3 Adults
3.4 Children
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Live Vaccines Production Capacity Market Share by Manufacturers
4.2 Global Live Vaccines Revenue Market Share by Manufacturers
4.3 Global Live Vaccines Average Price by Manufacturers
5. Company Profiles and Key Figures in Live Vaccines Business
5.1 Merck
5.1.1 Merck Company Profile
5.1.2 Merck Live Vaccines Product Specification
5.1.3 Merck Live Vaccines Production Capacity, Revenue, Price and Gross Margin
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Company Profile
5.2.2 GlaxoSmithKline Live Vaccines Product Specification
5.2.3 GlaxoSmithKline Live Vaccines Production Capacity, Revenue, Price and Gross Margin
5.3 Pfizer
5.3.1 Pfizer Company Profile
5.3.2 Pfizer Live Vaccines Product Specification
5.3.3 Pfizer Live Vaccines Production Capacity, Revenue, Price and Gross Margin
5.4 Novartis
5.4.1 Novartis Company Profile
5.4.2 Novartis Live Vaccines Product Specification
5.4.3 Novartis Live Vaccines Production Capacity, Revenue, Price and Gross Margin
5.5 Astellas Pharma
5.5.1 Astellas Pharma Company Profile
5.5.2 Astellas Pharma Live Vaccines Product Specification
5.5.3 Astellas Pharma Live Vaccines Production Capacity, Revenue, Price and Gross Margin
5.6 Emergent BioSolutions
5.6.1 Emergent BioSolutions Company Profile
5.6.2 Emergent BioSolutions Live Vaccines Product Specification
5.6.3 Emergent BioSolutions Live Vaccines Production Capacity, Revenue, Price and Gross Margin
5.7 AstraZeneca
5.7.1 AstraZeneca Company Profile
5.7.2 AstraZeneca Live Vaccines Product Specification
5.7.3 AstraZeneca Live Vaccines Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Live Vaccines Market Size
6.2 North America Live Vaccines Key Players in North America
6.3 North America Live Vaccines Market Size by Type
6.4 North America Live Vaccines Market Size by Application
7. East Asia
7.1 East Asia Live Vaccines Market Size
7.2 East Asia Live Vaccines Key Players in North America
7.3 East Asia Live Vaccines Market Size by Type
7.4 East Asia Live Vaccines Market Size by Application
8. Europe
8.1 Europe Live Vaccines Market Size
8.2 Europe Live Vaccines Key Players in North America
8.3 Europe Live Vaccines Market Size by Type
8.4 Europe Live Vaccines Market Size by Application
9. South Asia
9.1 South Asia Live Vaccines Market Size
9.2 South Asia Live Vaccines Key Players in North America
9.3 South Asia Live Vaccines Market Size by Type
9.4 South Asia Live Vaccines Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Live Vaccines Market Size
10.2 Southeast Asia Live Vaccines Key Players in North America
10.3 Southeast Asia Live Vaccines Market Size by Type
10.4 Southeast Asia Live Vaccines Market Size by Application
11. Middle East
11.1 Middle East Live Vaccines Market Size
11.2 Middle East Live Vaccines Key Players in North America
11.3 Middle East Live Vaccines Market Size by Type
11.4 Middle East Live Vaccines Market Size by Application
12. Africa
12.1 Africa Live Vaccines Market Size
12.2 Africa Live Vaccines Key Players in North America
12.3 Africa Live Vaccines Market Size by Type
12.4 Africa Live Vaccines Market Size by Application
13. Oceania
13.1 Oceania Live Vaccines Market Size
13.2 Oceania Live Vaccines Key Players in North America
13.3 Oceania Live Vaccines Market Size by Type
13.4 Oceania Live Vaccines Market Size by Application
14. South America
14.1 South America Live Vaccines Market Size
14.2 South America Live Vaccines Key Players in North America
14.3 South America Live Vaccines Market Size by Type
14.4 South America Live Vaccines Market Size by Application
15. Rest of the World
15.1 Rest of the World Live Vaccines Market Size
15.2 Rest of the World Live Vaccines Key Players in North America
15.3 Rest of the World Live Vaccines Market Size by Type
15.4 Rest of the World Live Vaccines Market Size by Application
16 Live Vaccines Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Global Live Vaccines Market Segmentation
By Vaccine Type
-
Monovalent Live Vaccines
-
Multivalent Live Vaccines
By Disease Indication
-
Measles, Mumps & Rubella (MMR)
-
Varicella
-
Rotavirus
-
Yellow Fever
-
Oral Polio Vaccine (OPV)
-
Others
By Age Group / Application
-
Children
-
Adults
By End User
-
Public Immunization Programs
-
Hospitals & Clinics
-
Travel & Specialty Vaccination Centers
